PRCT Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

93.70M

+37.32%

-0.323

-7.72%

92.20M

+33.31%

-0.312

-30.7%

102.59M

+29.56%

-0.277

-20.81%

Estimates Revision

The market is revising Downward the revenue expectations for PROCEPT BioRobotics Corporation (PRCT) for FY2025, with the revenue forecasts being adjusted by -0.02% over the past three months. During the same period, the stock price has changed by -5.00%.

Revenue Estimates for FY2025

Revise Downward

-0.02%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+1.65%

In Past 3 Month

Stock Price

Go Down

-5.00%

In Past 3 Month

9 Analyst Rating

Wall Street analysts forecast PRCT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRCT is 52.83 USD with a low forecast of 50.00 USD and a high forecast of 65.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

1 Hold

0 Sell

Strong Buy

Current: 36.100

Low

50.00

Averages

52.83

High

65.00

Current: 36.100

Low

50.00

Averages

52.83

High

65.00

UBS

Danielle Antalffy

Buy

initiated

$62

2025-12-12

New

Reason

UBS

Danielle Antalffy

Price Target

$62

2025-12-12

New

initiated

Buy

Reason

UBS analyst Danielle Antalffy initiated coverage of Procept BioRobotics with a Buy rating and $62 price target. The firm's key onion leader checks provide conviction in the company's utilization growth in 2026 and 2027. It views the recent selloff in the shares as a buying opportunity. Procept's focus on driving utilization on its existing installed base, underpenetrated system placement market, and mix-driven margin expansion are underappreciated by the market, the analyst tells investors in a research note.

BofA

Buy

Neutral

downgrade

$55 -> $38

2025-12-08

Reason

BofA

Price Target

$55 -> $38

2025-12-08

downgrade

Buy

Neutral

Reason

BofA downgraded Procept BioRobotics to Neutral from Buy with a price target of $38, down from $55.

BofA

Buy

Neutral

downgrade

$55 -> $38

2025-12-08

Reason

BofA

Price Target

$55 -> $38

2025-12-08

downgrade

Buy

Neutral

Reason

As previously reported, BofA downgraded Procept BioRobotics to Neutral from Buy with a price target of $38, down from $55. Procept still has a large potential market opportunity with its aquablation technology to treat benign prostatic hyperplasia, but utilization growth has slowed and changes in the works aimed at improving utilization could cause some near-term disruption, the analyst tells investors. Utilization growth and systems both slowing "doesn't instill confidence in upside," the analyst tells investors.

Morgan Stanley

Patrick Wood

Overweight

downgrade

$56 -> $51

2025-12-02

Reason

Morgan Stanley

Patrick Wood

Price Target

$56 -> $51

2025-12-02

downgrade

Overweight

Reason

Morgan Stanley analyst Patrick Wood lowered the firm's price target on Procept BioRobotics to $51 from $56 and keeps an Overweight rating on the shares. Going into 2026, MedTech "looks well-positioned on several fronts" as the firm thinks major product cycles and a supportive hospital spending environment, combined with trough valuations, make for "a solid industry setup," the analyst tells investors in a note for the group on the upcoming year.

TD Cowen

Buy

downgrade

$85 -> $50

2025-11-05

Reason

TD Cowen

Price Target

$85 -> $50

2025-11-05

downgrade

Buy

Reason

TD Cowen lowered the firm's price target on Procept BioRobotics to $50 from $85 and keeps a Buy rating on the shares. The firm said the stock reaction to its inline sales guidance seems overdone and the believe the company is being conservative.

Piper Sandler

Matt O'Brien

Overweight

downgrade

$55 -> $50

2025-11-05

Reason

Piper Sandler

Matt O'Brien

Price Target

$55 -> $50

2025-11-05

downgrade

Overweight

Reason

Piper Sandler analyst Matt O'Brien lowered the firm's price target on Procept BioRobotics to $50 from $55 and keeps an Overweight rating on the shares. The firm notes the company reported Q3 results that beat on sales and adjusted EBITDA. Management reiterated FY25 guidance and introduced FY26 sales guidance that brackets the Street's estimate. Piper suspects bears will focus on the soft utilization performance in the quarter and inventory destocking. That said, the firm believes these items reflect some of the organizational changes in the business, which could create transient issues but ultimately set up the business for positive momentum looking forward.

Valuation Metrics

The current forward P/E ratio for Procept Biorobotics Corp (PRCT.O) is -30.33, compared to its 5-year average forward P/E of -27.71. For a more detailed relative valuation and DCF analysis to assess Procept Biorobotics Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-27.71

Current PE

-30.33

Overvalued PE

-13.69

Undervalued PE

-41.72

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-52.48

Current EV/EBITDA

-140.05

Overvalued EV/EBITDA

-9.90

Undervalued EV/EBITDA

-95.06

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

14.36

Current PS

5.08

Overvalued PS

22.13

Undervalued PS

6.58

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 465.92% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

PRCT News & Events

Events Timeline

No data

News

4.5

12-08NASDAQ.COM

ETFs on the Move This Monday: REMX, IHI

1.0

11-21NASDAQ.COM

PROCEPT BioRobotics to Highlight Aquablation Expansion at Upcoming Piper Sandler Event

6.0

11-05Benzinga

TD Cowen Keeps Buy Rating on PROCEPT BioRobotics, Reduces Price Target to $50

People Also Watch

Frequently Asked Questions

What is Procept Biorobotics Corp (PRCT) stock price today?

The current price of PRCT is 36.1 USD — it has increased 0.31 % in the last trading day.

What is Procept Biorobotics Corp (PRCT)'s business?

PROCEPT BioRobotics Corporation is a commercial-stage surgical robotics company. The Company is focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AQUABEAM Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia (BPH). The Company's proprietary AQUABEAM Robotic System delivers Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. Aquablation therapy delivers effective, safe and durable outcomes for males suffering from lower urinary tract symptoms (LUTS), due to BPH, which are independent of prostate size and shape or surgeon experience.

What is the price predicton of PRCT Stock?

What is Procept Biorobotics Corp (PRCT)'s revenue for the last quarter?

Procept Biorobotics Corp revenue for the last quarter amounts to 83.33M USD, increased 42.76 % YoY.

What is Procept Biorobotics Corp (PRCT)'s earnings per share (EPS) for the last quarter?

Procept Biorobotics Corp. EPS for the last quarter amounts to -0.38 USD, decreased -5.00 % YoY.

What changes have occurred in the market's expectations for Procept Biorobotics Corp (PRCT)'s fundamentals?

How many employees does Procept Biorobotics Corp (PRCT). have?

Procept Biorobotics Corp (PRCT) has 756 emplpoyees as of December 15 2025.

What is Procept Biorobotics Corp (PRCT) market cap?

Today PRCT has the market capitalization of 2.01B USD.